Bandwidth Inc vs Pfizer Inc — how do they compare? Bandwidth Inc trades at $76.04 (market cap $2.36B), while Pfizer Inc trades at $24.29 (market cap $138.21B). The key difference: Pfizer Inc is far larger — about 58.6× Bandwidth Inc's market cap, and Pfizer Inc pays a 7.09% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | PFE | |
|---|---|---|
Market Cap | $2.36B | $138.21B |
Sector | Technology | Health |
52-Week High | $78.44 | $28.56 |
52-Week Low | $12.82 | $23.29 |
Enterprise Value | $2.74B | $188.87B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.09% |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.
The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.
Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.
The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →